P21 (Adamax)

P21 (P021) is a synthetic pentapeptide (Ac-DGGLAG-NH2; MW 578.3 g/mol) derived from amino acid residues 148-151 of ciliary neurotrophic factor (CNTF). Full-length CNTF fails as a therapeutic due to poor blood-brain barrier penetration and systemic side effects including anorexia and myalgia. P21 appends an adamantane-modified glycine at its C-terminus, improving lipophilicity and resistance to exopeptidase degradation; plasma half-life exceeds three hours in rodent models, with greater than 95% stability in artificial intestinal fluid.

In the central nervous system, P21 acts through two converging pathways. It competitively inhibits leukemia inhibitory factor (LIF) signaling, disinhibiting neurogenesis in the dentate gyrus subgranular zone. Simultaneously it increases BDNF transcription; elevated BDNF activates TrkB, engaging the PI3K-AKT cascade and leading to inhibitory phosphorylation of glycogen synthase kinase-3β (GSK-3β) at Ser9. Because GSK-3β is a major tau kinase, its inactivation reduces aberrant tau hyperphosphorylation. Downstream, P21 upregulates synaptic scaffolding proteins PSD-95, synaptophysin, synapsin-1, and the dendritic marker MAP2.

Adamax, a related but structurally distinct compound, replaces the CNTF-derived core with an N-acetyl semax backbone while retaining the C-terminal adamantyl group; both compounds increase BDNF but do so via different upstream mechanisms.

All published evidence for P21 comes from preclinical animal studies, the majority originating from a single research group at the New York State Institute for Basic Research (NYSIBR/SUNY Downstate). No human clinical trials have been conducted or registered as of mid-2026.

Li et al. (2010, FEBS Letters 584:3359-3365) first demonstrated that peripheral administration of P21 improved learning, short-term recognition memory, and spatial reference memory in normal adult C57Bl6 mice, and increased neurogenesis and dendritic complexity in the dentate gyrus granule cell layer.

A 12-month dietary oral study in 3xTg-AD transgenic Alzheimer's mice (60 nmol/g feed), reviewed by Kazim and Iqbal (2016, Mol Neurodegeneration 11:50; PMID 27400746), documented significant reduction in tau hyperphosphorylation at Ser262, Ser356, Ser396, and Ser404, attenuation of amyloid-beta pathology, rescue of dentate gyrus neurogenesis, and reversal of cognitive deficits in the Morris water maze and object location tasks.

An 18-month extension study (PMID 28655344, Alzheimer's Res Ther 2017; n=32 treated mice) reported rescue of PSD-95, synaptophysin, and synapsin-1 expression; restoration of MAP2-positive dendritic arbors; and improvement in both spatial and recognition memory. No severe adverse effects occurred over the full treatment period.

Kazim et al. (Sci Rep 2017; PMID 28368015; n=70 mice) tested prenatal-to-postnatal P21 in the Ts65Dn Down syndrome model, completely rescuing Morris water maze deficits and partially improving object recognition, with effects persisting into adulthood after dosing ended at postnatal day 21.

A 2024 study in a CDKL5 deficiency model (PMID 39592934) found positive in vitro results but failed to normalize neurogenesis or neuronal morphology with oral P21 in vivo, underscoring limits of cross-model translation. A 2026 diffusion MRI study (PMID 41740658) observed white matter microstructure normalization in treated 3xTg-AD mice but acknowledged the absence of behavioral data as a key limitation. Independent replication outside the originating laboratory remains limited.

Typical dosage: 5-20 mg (intermittent).

In published animal studies, P21 has been delivered orally via formulated diet at 60 nmol per gram of feed, yielding roughly 160-200 nmol per mouse per day across multiple studies. Prenatal studies used 200 nM/g feed. Injection experiments in rodents employed up to 750 nmol per mouse per day. These doses cannot be directly translated to human equivalents in the absence of published dose-scaling or human pharmacokinetic data.

In the research peptide community, the following protocols are reported anecdotally and are not supported by any human clinical trial data:

• Subcutaneous injection: 100-500 micrograms per day, typically cycled over 4-6 weeks • Intranasal administration: 500 micrograms to 1 mg per day for general use; some users report escalating to 2-4 mg per day for more acute effects • Oral route: preclinical models demonstrate greater than 95% stability in simulated intestinal fluid and a plasma half-life exceeding three hours, suggesting oral feasibility; however, no human oral dose has been established in any study

P21 is not approved by the FDA or any equivalent regulatory agency and is sold only as a research compound. The protocols above are drawn from community sources and the International Peptide Society monograph, not from controlled human trials. This information is educational in nature and does not constitute medical advice; individuals should consult a qualified healthcare professional before using any unapproved compound.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

No controlled preclinical or human study has examined combination regimens incorporating P21. All information on stacking is anecdotal, originating from online peptide communities and biohacker forums.

The most frequently discussed combination pairs P21 with Adamax. The theoretical rationale is complementary BDNF-pathway modulation: P21 is proposed to increase BDNF production at the transcriptional level, while Adamax is proposed to sensitize hippocampal TrkB receptors to BDNF. Whether this produces additive or synergistic effects in humans is entirely unknown and the mechanistic claim rests on inference from each compound's individual preclinical profile, not from combined-exposure studies.

Some users anecdotally report adding BPC-157 for broader neuroprotective coverage, citing that compound's interactions with the dopaminergic system. Combinations with Selank or Semax analogs have also been mentioned for BDNF augmentation. All such stacks lack any evidence base. Stacking compounds that converge on the BDNF-TrkB pathway raises a theoretical concern about excessive pathway stimulation and downstream effects on anxiety regulation and pain sensitivity, though this has not been studied experimentally.

P21 (Adamax) is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Research compound, limited data

In rodent studies spanning up to 18 months of continuous dietary administration, P21 has not produced significant adverse effects. No weight loss, tumor formation, organ pathology, or neurological signs were observed at therapeutic doses. This profile contrasts favorably with full-length CNTF, which causes anorexia, severe muscle cramps, and systemic weight loss at therapeutic concentrations. The originating research group reported no adverse effects at approximately 550-fold the rodent therapeutic dose.

No controlled human safety study has been conducted. Anecdotal adverse effects reported in the peptide community include injection-site redness and pain, mild headache, and transient fatigue; these reports are not systematically collected and cannot substitute for a validated safety profile.

A theoretical immunogenicity concern warrants mention: full-length CNTF elicited neutralizing antibodies in prior human clinical trials for amyotrophic lateral sclerosis. P21, being far smaller, has not triggered an antibody response in rodent studies to date, but human immunogenicity data are absent. Pathologically elevated BDNF has been associated in some research contexts with anxiety-related behavior and altered pain sensitivity, suggesting compounds that strongly upregulate BDNF merit caution at supra-therapeutic doses.

P21 is not approved by the FDA or any equivalent regulatory agency. Its long-term safety in humans is entirely unknown, and its use in humans constitutes off-label, unregulated self-experimentation.